ANI Pharmaceuticals
ANIP
158 hedge funds and large institutions have $320M invested in ANI Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 62 increasing their positions, 40 reducing their positions, and 24 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 40
29% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 24
1.68% more ownership
Funds ownership: 54% → 55.68% (+1.7%)
1% more funds holding
Funds holding: 157 → 158 (+1)
16% less capital invested
Capital invested by funds: $379M → $320M (-$59.7M)
85% less call options, than puts
Call options by funds: $2.71M | Put options by funds: $18M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$63.5M |
| 2 |
First Manhattan
New York
|
+$15.6M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.83M |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$4.61M |
| 5 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$3.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$19.6M |
| 2 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
-$9.09M |
| 3 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
-$3.06M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$2.71M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.48M |
ANIP Hedge Fund Activity: Q1 2017 in Review
158 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q1 2017, worth a combined $320M — down 16% from $379M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ANIP positions and 24 closed out — a net gain of 7 holders — while 62 added to existing stakes and 40 trimmed.
The largest buyer was BlackRock, adding an estimated $63.5M. The largest seller was Consonance Capital Management, cutting an estimated $19.6M.
- 158 institutional investors held ANI Pharmaceuticals (ANIP) as of Q1 2017, up from 157 in Q4 2016.
- Funds reported $320M of ANI Pharmaceuticals stock for Q1 2017, down 16% quarter-over-quarter.
- 31 funds opened new ANI Pharmaceuticals positions in Q1 2017 and 24 closed out, a net change of +7 holders.
- The largest ANI Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $63.5M added.
- The largest ANI Pharmaceuticals seller in Q1 2017 was Consonance Capital Management, an estimated $19.6M sold.
Based on aggregated 13F filings for Q1 2017.